Previous studies have shown that KLK3 plays a critical role in inhibiting prostate cancer progression and restoring chemotherapy sensitivity [19], while PAGE4 has been reported to significantly enhance tumor cell responsiveness to gefitinib and other therapies [20] (Figure 2E and Supplementary Figure S2). This evidence concerns the gene KLK3 and neoplasm.